Related Experiment Video
Updated: May 29, 2026
08:22
In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
Published on: October 27, 2020
Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism.
Jiangquan Zhou1, Philip E Empey, Robert R Bies
1Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261, USA.
Summary
Mild therapeutic hypothermia and cardiac arrest (CA) alter drug metabolism. This study found that hypothermia and CA significantly reduce the activity of key drug-metabolizing enzymes, impacting drug disposition.
Area of Science:
- Pharmacology
- Toxicology
- Physiology
Background:
- Mild therapeutic hypothermia is a neuroprotection strategy after cardiac arrest (CA).
- The combined effects of hypothermia and CA on drug metabolism are not fully understood.
- Understanding these effects is crucial for optimizing drug therapy in post-CA patients.
Purpose of the Study:
- To investigate the impact of hypothermia and CA on the activity of major hepatic drug-metabolizing enzymes.
- To evaluate how these conditions alter the pharmacokinetics of probe drugs metabolized by CYP3A, CYP2C, CYP2D, and CYP2E enzymes.
- To determine the specific effects of hypothermia, CA, and their interaction on drug disposition.
Main Methods:
- Experimental study in rats subjected to sham normothermia, CA normothermia, sham hypothermia, and CA hypothermia.
- Simultaneous intravenous administration of probe drugs: midazolam (CYP3A), diclofenac (CYP2C), dextromethorphan (CYP2D), and chlorzoxazone (CYP2E).
- Pharmacokinetic (PK) analysis using noncompartmental and population PK modeling to assess drug clearance and volume of distribution.
Main Results:
- CA hypothermia significantly reduced the clearance of midazolam (CYP3A) and chlorzoxazone (CYP2E) compared to sham normothermia.
- Population PK analysis confirmed decreased midazolam and chlorzoxazone clearance associated with CA injury.
- Hypothermia was linked to a decreased volume of distribution for midazolam, dextromethorphan, and chlorzoxazone.
Conclusions:
- Hypothermia and cardiac arrest, individually and interactively, alter cytochrome P450 enzyme activities.
- These alterations are isoform-specific, affecting drug disposition in a complex manner.
- The findings highlight the need to consider hypothermia and CA when managing drug therapy in patients.
Related Concept Videos
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:29Decreased Body Temperature
A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by sustained extreme cold exposure, and severe...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...